WO2011049053A1 - Cellules myéloïdes inhérentes à la muqueuse intestinale inhibant l'activation des lymphocytes t et leur utilisation - Google Patents
Cellules myéloïdes inhérentes à la muqueuse intestinale inhibant l'activation des lymphocytes t et leur utilisation Download PDFInfo
- Publication number
- WO2011049053A1 WO2011049053A1 PCT/JP2010/068305 JP2010068305W WO2011049053A1 WO 2011049053 A1 WO2011049053 A1 WO 2011049053A1 JP 2010068305 W JP2010068305 W JP 2010068305W WO 2011049053 A1 WO2011049053 A1 WO 2011049053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cd11c
- cd11b
- cell
- myeloid
- Prior art date
Links
- 210000000066 myeloid cell Anatomy 0.000 title claims abstract description 91
- 230000006044 T cell activation Effects 0.000 title claims abstract description 34
- 230000002401 inhibitory effect Effects 0.000 title claims description 12
- 230000000968 intestinal effect Effects 0.000 title description 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract description 214
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract description 214
- 102100022297 Integrin alpha-X Human genes 0.000 claims abstract description 202
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 53
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 109
- 101150099493 STAT3 gene Proteins 0.000 claims description 48
- 230000014509 gene expression Effects 0.000 claims description 45
- 210000003289 regulatory T cell Anatomy 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 21
- 230000006907 apoptotic process Effects 0.000 claims description 18
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 11
- 101150024938 HPGD gene Proteins 0.000 claims description 10
- 230000011664 signaling Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000005206 intestinal lamina propria Anatomy 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 abstract description 11
- 230000002584 immunomodulator Effects 0.000 abstract description 9
- 229940121354 immunomodulator Drugs 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000033540 T cell apoptotic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 281
- 241000699670 Mus sp. Species 0.000 description 62
- 230000002950 deficient Effects 0.000 description 49
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 30
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 30
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 30
- 210000002429 large intestine Anatomy 0.000 description 26
- 210000001072 colon Anatomy 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000000684 flow cytometry Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000006052 T cell proliferation Effects 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 208000004232 Enteritis Diseases 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000000412 Annexin Human genes 0.000 description 6
- 108050008874 Annexin Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 230000000112 colonic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101150004620 Cebpb gene Proteins 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 210000005081 epithelial layer Anatomy 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 4
- 101150085950 IL10 gene Proteins 0.000 description 4
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 4
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 4
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000005007 innate immune system Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 101150106931 IFNG gene Proteins 0.000 description 3
- 101150098378 Il17a gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 210000000068 Th17 cell Anatomy 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010049040 Weight fluctuation Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000010227 enterocolitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150044653 HMOX1 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000752249 Homo sapiens Rho guanine nucleotide exchange factor 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102100021689 Rho guanine nucleotide exchange factor 3 Human genes 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- -1 phosphoryl acetate Chemical compound 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
Definitions
- the present invention relates to a myeloid cell peculiar to the intestinal mucosa that suppresses T cell activation and its use, and more specifically, a myeloid cell that is present in the lamina intestinal mucosa and suppresses T cell activation, and the myeloid
- the present invention relates to a method for inhibiting T cell activation using cells, a method for inducing apoptosis of T cells, and an immunomodulator.
- Inflammatory bowel disease is a general term for diseases that cause chronic inflammation or ulceration in the mucosa of the large and small intestines. Causes of intestinal bacteria, abnormal autoimmune reactions, or eating habits Involvement of change is estimated, but it has not been clarified yet. Inflammatory bowel diseases are classified into two diseases, ulcerative colitis and Crohn's disease, both of which are designated as specific diseases by the Ministry of Health, Labor and Welfare's specific disease treatment research project. Although it has been said that there are many diseases in developed countries in Europe and the United States, the number of patients has increased rapidly in Japan in recent years.
- Non-patent Documents 1 and 2 have been reported.
- Non-patent Document 3 CD11b + CD11c + CD70 + cells existing in the lamina intestinal tract are reported to induce Th17 cells that are inflammatory effector cells.
- Gr-1 high CD11b + cells Myeloid-derived suppressor cells (MDSCs) induced in peripheral blood and spleen due to cancer, inflammation, infection, etc. suppress T cell responses.
- MDSCs Myeloid-derived suppressor cells
- innate immune system cell subsets are already known in cells in the lamina intestinal mucosa, but there may be a subset of innate immune system cells that have not yet been found. Among them, it can be expected that cells useful for elucidating the onset mechanism of inflammatory bowel disease and developing therapeutic methods will be found.
- the present invention finds a novel cell population that is present in the lamina intestinal tract and can suppress the onset of inflammation by suppressing T cell activation, and is useful for the prevention or treatment of inflammatory bowel disease and the like.
- An object is to provide an immunomodulator.
- the present invention includes the following inventions in order to solve the above problems.
- the expression level of a gene whose expression is induced by IL-10 / Stat3 signaling is compared with that of myeloid cells of Gr-1 low positive, CD11b positive, and CD11c positive that are present in the lamina intestinal mucosa.
- a method for inhibiting T cell activation comprising contacting the myeloid cell according to any one of [1] to [7] above with a T cell stimulated with TCR.
- a method for inducing apoptosis of T cells comprising contacting the myeloid cells according to any one of [1] to [7] above with T cells stimulated with TCR.
- An immunomodulator comprising the myeloid cell according to any one of [1] to [7] as an active ingredient.
- a preventive or therapeutic agent for inflammatory bowel disease comprising the myeloid cell according to any one of [1] to [7] as an active ingredient.
- An immunomodulating method comprising administering an effective amount of the myeloid cell according to any one of [1] to [7] to a mammal.
- a method for preventing or treating inflammatory bowel disease comprising administering an effective amount of the myeloid cell according to any one of [1] to [7] to a mammal.
- [15] Use of the myeloid cell according to any one of [1] to [7] above for producing a preventive or therapeutic agent for inflammatory bowel disease.
- the myeloid cells of the present invention are present in the lamina intestinal mucosa and can suppress the activation of T cells by inducing apoptosis of T cells without inducing regulatory T cells. Therefore, the myeloid cell of the present invention is very useful as an active ingredient of an immunomodulator.
- (A) is a figure which shows the result of having performed flow cytometry analysis about colon
- (B) is Gr about CD11b + CD11c + cell.
- (C) shows May-Grunwald-Giemsa staining of Gr-1 low CD11b + CD11c + cells and Gr-1 high CD11b + CD11c + cells, respectively. It is the photograph observed with a microscope.
- A shows flow cytometric analysis of (I) colon LP cells, (II) spleen cells, (III) peripheral blood cells, (IV) bone marrow cells, and (V) intestinal lymph node cells, using CD11b and Gr-1 as indicators.
- B shows the flow of CD11c as an index for Gr-1 high CD11b + cells in (I) colon LP cells, (II) spleen cells, (III) peripheral blood cells, and (IV) bone marrow cells. It is a figure which shows the result of having performed cytometry analysis.
- FIG. CD4 + CD25 ⁇ T cells and Gr-1 low CD11b + CD11c + cells are co-cultured in the presence of anti-CD3 antibody, or CD4 + CD25 ⁇ T cells and Gr-1 low CD11b + CD11c + cells and Gr-1 high It is a figure which shows the result of having measured the cell proliferation at the time of coculturing with CD11b + CD11c + cell.
- FIG. 6 is a diagram showing the results of real-time RT-PCR. Inflammation in CD4 + T cells in colonic LP cells collected from CD4 + CD45RB high administration group (positive control group) and CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration group (test substance administration group), respectively It is a figure which shows the result of having analyzed the expression of protein by flow cytometry.
- CD4 + CD45RB high dose group (positive control group), and CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration group CD4 + T cells in the lymphocyte colon LP cells taken from each of (test substance administration group) It is a figure which shows the real value of.
- (B) shows CD4 + CD25 ⁇ T cells and wild-type mouse-derived Gr-1 low CD11b + CD11c + cells in the presence of anti-CD3 antibody. It is a figure which shows the result of having measured the cell proliferation at the time of coculturing with IL-10 deficient mouse origin Gr-1 high CD11b + CD11c + cell. It is a figure which shows the result of having confirmed that the T cell proliferation inhibitory ability was recovered by applying IL-10 stimulation with respect to IL-10 deficient mouse-derived Gr-1 high CD11b + CD11c + cells.
- CD4 + T cells were collected from the spleen of myeloid cell-specific Stat3-deficient mice (LysM-Cre; Stat3 F / F ) administered with wild-type Gr-1 high CD11b + CD11c + cells, and cultured after stimulation with anti-CD3 antibody It is a figure which shows the result of having measured the IFN- ⁇ density
- the present invention provides a myeloid cell that is present in the lamina intestinal tract and suppresses T cell activation without inducing regulatory T cells.
- the present inventors have found an unknown cell population that can suppress T cell activation in the lamina intestinal tract, and the cells constituting this unknown cell population are: T cell activation is suppressed by a mechanism that has not been reported so far, in which T cell activation is suppressed by inducing apoptosis of T cells rather than through T regulatory cells. It was found to be myeloid cells to be suppressed.
- Inhibition of T cell activation includes, for example, when the myeloid cells of the present invention and T cells are co-cultured in the presence of a T cell stimulating molecule such as an antigen, and only T cells are cultured in the presence of a T cell stimulating molecule. It can be confirmed by comparing the proliferation of T cells in each case and suppressing the proliferation of T cells in co-culture.
- Not inducing regulatory T cells means that, for example, when the myeloid cells of the present invention and T cells are co-cultured in the presence of a T cell stimulating molecule such as an antigen, a marker for regulatory T cells (eg, IL-10) ) Is not expressed.
- Inducing apoptosis of T cells can be achieved by, for example, co-culturing the myeloid cells of the present invention and T cells in the presence of a T cell stimulating molecule such as an antigen, and then staining with annexin. In the presence of T cell stimulating molecules).
- a T cell stimulating molecule such as an antigen
- the myeloid cells of the present invention are characterized by being present in the intestinal mucosa lamina intestinal of healthy animals. So far, it has been reported that myeloid cells that suppress T cell activation are induced in peripheral blood and spleen without inducing regulatory T cells when cancer, inflammation, infection, etc. develop. (Non-patent Documents 4 and 5), there is no report that such cells were found in healthy animals. Therefore, the myeloid cell of the present invention found and successfully isolated by the present inventors is a novel cell that has not been known at all.
- the myeloid cells of the present invention are Gr-1 high positive, CD11b positive, and CD11c positive cells.
- CD11b positive means not CD11b negative.
- CD11b negative means that in the flow cytometry analysis, the cells stained with the fluorescently labeled anti-CD11b antibody have the same level of staining as the control cells stained with the unstained or non-stained control antibody. When the staining level of the analysis target cell is higher than the staining level of the control cell, it can be determined that the CD11b is positive. The same applies to CD11c positive.
- the present inventors do not have Gr-1 (granulocyte-differentiation antigen-1) negative cells among CD11b-positive and CD11c-positive cells in cells in the lamina intestinal mucosa, but among the positive cells It was found that there are Gr-1 high positive cells and Gr-1 low positive cells.
- Gr-1 high positive cells are cells with high Gr-1 expression levels
- Gr-1 low positive cells are cells with low Gr-1 expression levels, which can be easily distinguished by flow cytometry analysis.
- myeloid cells of the present invention suppress T cell activation by activating their Stat3 in the presence of IL-10. That is, the myeloid cell of the present invention is stimulated by the anti-inflammatory cytokine IL-10, and its transcription factor Stat3 is activated, and the IL-10 / Stat3 signaling system is activated in the cell, The ability to suppress T cell activation can be obtained.
- IL-10 is always produced from macrophages and regulatory T cells by stimulation of intestinal bacteria and dietary antigens, and the present invention exists in the lamina intestinal mucosa of healthy animals. Since myeloid cells are always stimulated with IL-10, it can be said that they are myeloid cells that have acquired the ability to suppress T cell activation.
- the myeloid cells of the present invention are characterized by a high expression level of a gene whose expression is induced by IL-10 / Stat3 signaling.
- genes whose expression is induced by IL-10 / Stat3 signaling include the genes described in Table 1 of Example 5.
- the expression level of these genes in the myeloid cells of the present invention should be at least 3 times the expression level of Gr-1 low positive, CD11b positive, and CD11c positive myeloid cells present in the lamina intestinal tract. , Preferably 4 times or more. Comparison of gene expression levels can be performed by known methods such as DNA microarray method, RT-PCR method, real-time RT-PCR method and the like.
- the present inventors have used the real-time RT-PCR method to determine the myeloid of the present invention for five genes Hpgd, Cd163, Hmoxl, Cd209f and Cd209g among the genes whose expression is induced by IL-10 / Stat3 signaling. It has been confirmed that the expression level of the cells is at least four times the expression level of Gr-1 low positive, CD11b positive, and CD11c positive myeloid cells present in the lamina intestinal tract.
- the method for obtaining myeloid cells of the present invention is not particularly limited.
- the cell sorter is isolated and collected from the lamina intestinal tract and stained with fluorescently labeled anti-Gr-1, anti-CD11b and anti-CD11c antibodies.
- high positive is referred to as high and low positive is referred to as low (for example, Gr-1 high positive is "Gr-1 high ", Gr-1 low positive is "Gr-1 low ").
- the positive +, negative - and referred to for example, CD11b positive "CD11b +", CD11b negative "CD11b -").
- the present invention provides a method for inhibiting T cell activation.
- the present invention also provides a method for inducing apoptosis of T cells.
- the method for inhibiting T cell activation according to the present invention or the method for inducing apoptosis of T cells according to the present invention comprises contacting the myeloid cells of the present invention with T cells stimulated with TCR (T cell receptor: T ⁇ ⁇ cell receptor). As long as it contains.
- TCR T cell receptor: T ⁇ ⁇ cell receptor
- the contact start time of the myeloid cell of the present invention and the T cell is not limited, and may be before the T cell is subjected to the TCR stimulation, after the TCR stimulation, or simultaneously.
- the present invention provides an immunomodulator comprising the myeloid cell of the present invention as an active ingredient. Since the myeloid cells of the present invention can induce apoptosis of T cells and suppress the activation of T cells, when the immune response is abnormally enhanced in vivo, an undesirable immune response occurs in vivo. When the myeloid cells of the present invention are administered in cases where it is predicted that an undesirable immune reaction will occur in the future, abnormal immune responses and undesirable immune reactions can be suppressed or prevented.
- the immunomodulating agent of the present invention includes rejection in organ transplantation, allergic diseases (hay fever, food allergy, drug allergy, asthma, atopic dermatitis, eczema, food hypersensitivity, urticaria, allergic rhinitis, allergic conjunctivitis, etc. ), Autoimmune diseases (polymyositis, chronic rheumatism, systemic lupus erythematosis, systemic sclerosis, blistering, cutaneous lupus erythematosis, psoriasis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, multiple sclerosis, Such as type 1 diabetes), graft-versus-host disease (GVHD), and infertility.
- allergic diseases hay fever, food allergy, drug allergy, asthma, atopic dermatitis, eczema
- food hypersensitivity urticaria
- allergic rhinitis allergic conjunctivitis, etc.
- Autoimmune diseases polymyo
- the present inventors have confirmed that the onset of colitis in an inflammatory bowel disease model mouse is suppressed by administration of the myeloid cells of the present invention, and the myeloid cells of the present invention are inflammatory bowel diseases (Crohn's disease). , Ulcerative colitis) is suitable as an active ingredient of a preventive or therapeutic agent.
- the immunomodulator of the present invention can be produced by mixing an effective amount of the above-mentioned myeloid cells of the present invention with a pharmaceutically acceptable carrier according to known pharmaceutical production means.
- the immunomodulator of the present invention is usually produced as a parenteral preparation such as an injection, a suspension, an infusion.
- carriers that can be included in the parenteral preparation include aqueous solutions for injection such as isotonic solutions containing physiological saline, glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.). And so on.
- the immunomodulating agent of the present invention includes, for example, a buffer (eg, phosphate buffer, sodium acetate buffer, etc.), a soothing agent (eg, benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (eg, human Serum albumin, polyethylene glycol, etc.), preservatives, antioxidants and the like.
- the preparation thus obtained can be administered to, for example, humans and other mammals (eg, rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
- the myeloid cell of the present invention it is preferable to use the myeloid cell of the present invention derived from the administration subject animal according to the administration subject animal.
- the dose of the myeloid cells of the present invention varies depending on the administration subject, symptoms, administration method, etc. For example, in an adult human (with a body weight of 60 kg), the upper limit is about 6 ⁇ 10 9 cells per day. Administration is preferred.
- Example 1 Detailed examination of CD11b + CD11c + cells present in the lamina intestinal tract]
- (1-1) Experimental materials and methods
- C57BL / 6J mice were purchased from Japan SLC. All animal experiments were conducted according to the guidelines established by Osaka University.
- Isolation of cells from large intestine LP Isolation of large intestine LP cells was performed according to the method described in Non-Patent Document 3. That is, the large intestine was collected from euthanized C57BL / 6J mice, and after removing feces, it was immersed in HBSS containing 5 mM EDTA and treated at 37 ° C. for 15 minutes.
- RPMI1640 4% FBS, 1 mg / ml collagenase type II (Invitrogen), 1 mg / ml dissease (Invitrogen) and 40 ⁇ g / ml DNaseI (Roche (Including Diagnostics) and enzyme-treated at 37 ° C. for 1 hour using a shaker. After enzyme treatment, cells were isolated through a 40 ⁇ m cell strainer.
- CD11b + CD11c + cell population includes CD11b + CD11c + CD70 + cells that induce Th17 cells (Non-patent Document 3), but besides this subset that induces Th17 cells, Detailed analysis was performed on CD11b + CD11c + cells to confirm whether there is a subset involved in intestinal homeostasis.
- CD11b + CD11c + cells were further stained with biotin-labeled anti-Gr-1 antibody and APC-labeled streptavidin for flow cytometric analysis.
- the CD11b + CD11c + cells in the large intestine LP contained Gr-1 high CD11b + CD11c + cells with high Gr-1 expression. It was shown that Gr-1 low CD11b + CD11c + cells with low Gr-1 expression were present.
- these cells were stained with May-Grunwald-Giemsa and observed with a microscope, it was confirmed that all the cells were mononuclear cells (see FIG. 1C).
- Gr-1 high CD11b + cells in the spleen, peripheral blood, and bone marrow were collected and stained with FITC-labeled anti-CD11c antibody. Whether or not expressed CD11c was confirmed by flow cytometry analysis. The results are shown in FIG. As is clear from FIG. 2 (B), Gr-1 high CD11b + cells in spleen, peripheral blood, and bone marrow do not express CD11c, and Gr-1 high CD11b + CD11c + cells are not expressed in tissues other than colonic LP. Existence could not be confirmed. From these results, it was revealed that Gr-1 high CD11b + CD11c + cells exist specifically in the colon LP of healthy mice.
- Example 2 Functional examination of large intestine LP-derived Gr-1 high CD11b + CD11c + cells
- Gr-1 high CD11b + CD11c + cells and Gr-1 low CD11b + CD11c + cells were collected from colon LPs of C57BL / 6J mice using FACSAria. Cells were obtained from the spleens of C57BL / 6J mice and CD4 + CD25 ⁇ CD44 ⁇ CD62L + naive T cells or CD4 + CD25 ⁇ T cells were isolated using FACSAria.
- a 96-well U-bottom plate was used for the culture, and the culture was performed for 72 hours at 37 ° C. and 5% CO 2 . 56 ⁇ h after the start of the culture, 1 ⁇ Ci [ 3 H] thymidine was added to each well, and further cultured for 16 hours. Then, the cells were collected on a filter mat and the radioactivation ability was measured.
- the anti-CD3 antibody and the anti-CD28 antibody were both purchased from BD Pharmingen.
- As controls only CD4 + CD25 ⁇ T cells, Gr-1 low CD11b + CD11c + cells, and Gr-1 high CD11b + CD11c + cells were cultured in the presence of anti-CD3 antibody.
- a 96-well U-bottom plate was used for the culture, and the culture was performed for 72 hours at 37 ° C.
- Gr-1 high CD11b + CD11c + cells and Gr-1 low CD11b + CD11c + cells were collected from colon LPs of C57BL / 6J mice, and CD4 + CD25 + T cells were collected from spleen using FACSAria.
- 1 ⁇ 10 4 cells / well of CD4 + CD25 ⁇ T cells and 1 ⁇ 10 4 cells / well of Gr-1 low CD11b + CD11c + cells were co-cultured in a culture medium supplemented with anti-CD3 antibody (1 ⁇ g / ml soluble).
- Gr-1 high CD11b + CD11c + cells or CD4 + CD25 + T cells were added at various ratios and cultured at 37 ° C. under 5% CO 2 for 72 hours.
- 56 ⁇ h after the start of the culture 1 ⁇ Ci [ 3 H] thymidine was added to each well, and further cultured for 16 hours. Then, the cells were collected on a filter mat and the radioactivation ability was measured.
- naive T cells isolated from the spleen of C57BL / 6J mice were combined with Gr-1 high CD11b + CD11c + cells or Gr-1 low CD11b + CD11c + cells Co-cultured for 72 hours in the presence of anti-CD3 antibody (1 ⁇ g / ml soluble) at a ratio of 1: 1.
- anti-CD3 antibody (1 ⁇ g / ml soluble) at a ratio of 1: 1.
- 50 ng / ml phosphoryl acetate (PMA; Sigma) and 5 ⁇ M ionomycin (Sigma) were added and stimulated for 4 hours, and then RNA was obtained using TRIzol reagent (Invitrogen).
- RNA was subjected to real-time RT-PCR, and the expression levels of IFN- ⁇ gene (Ifng), IL-17a gene (Il17a) and IL-10 gene (Il10) were quantified. Specifically, the obtained RNA was treated with RQ1 DNase I (Promega), and reverse transcription was performed using M-MLV reverse reverse transcriptase (Promega) and random primer (Toyobo) to prepare cDNA.
- Real-time RT-PCR was performed on ABI 7300 real time PCR system (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) or PCR Master Mix (Applied Biosystems).
- EF-1 ⁇ was used as an internal standard gene, and each sample was standardized based on the expression level of EF-1 ⁇ .
- T cells co-cultured with Gr-1 high CD11b + CD11c + cells and T cells co-cultured with Gr-1 low CD11b + CD11c + cells are both markers of regulatory T cells.
- the expression of certain Il10 was not observed, suggesting that regulatory T cells are not involved in suppression of T cell activity induced by Gr-1 high CD11b + CD11c + cells.
- T cells co-cultured with Gr-1 high CD11b + CD11c + cells did not express not only Il10 but also effector T cell markers Ifng and Il17a, Gr-1 high CD11b + CD11c + Cells were shown not to be involved in the differentiation of effector T cells. This result suggests that Gr-1 high CD11b + CD11c + cells are not involved in T cell differentiation and induce T cell tolerance by acting directly on T cells via some molecule.
- Example 3 Examination using T cell-dependent mouse model of inflammatory bowel disease
- 3-1 Preparation of T cell-dependent inflammatory bowel disease model mice CD4 + CD45RB high cells derived from the spleen of Balb / c mice (CLEA Japan) were isolated using FACSAria, and SCID mice (CLEA Japan) 3 ⁇ 10 5 cells were transferred into the abdominal cavity (CD4 + CD45RB high administration group).
- mice (CLEA Japan) from the large intestine LP using FACSAria isolated Gr-1 high CD11b + CD11c + 3 ⁇ 10 5 cells to, CD4 + CD45RB high 3 ⁇ 10 5 cells simultaneously with SCID
- the mice were transferred into the peritoneal cavity (CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration group).
- PBS was administered to SCID mice (PBS administration group).
- FITC-labeled anti-CD45RB antibody (BD Pharmingen) and Percp-Cy5.5-labeled anti-CD4 antibody (Bio Legend) were used.
- the intestinal tract of the CD4 + CD45RB high administration group was significantly thicker than that of the PBS administration group, and epithelial layer shedding and massive inflammatory cell infiltration were observed.
- slight thickening was observed in the intestinal tract of the CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration group, but epithelial layer loss and inflammatory cell infiltration were not observed.
- the CD4 + CD45RB high administration group developed colitis due to the transfer of CD4 + CD45RB high cells, but the CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration group developed colitis. It became clear that it was suppressed.
- Il6 Probe 5'-ccttcttgggactgatgctggtgaca-3 '(SEQ ID NO: 9) Forward primer 5'-ctgcaagagacttccatccagtt-3 '(SEQ ID NO: 10) Reverse primer 5'-aagtagggaaggccgtggtt-3 '(SEQ ID NO: 11) Il12b Probe 5'-ctgcagggaacacatgcccacttg-3 '(SEQ ID NO: 12) Forward primer 5'-gctcaggatcgctattacaat-3 '(SEQ ID NO: 13) Reverse primer 5'-tcttccttaatgtcttccact-3 '(SEQ ID NO: 14)
- the cells were stained with FITC-labeled anti-IFN- ⁇ antibody (BD Pharmingen), PE-labeled anti-IL17 antibody (BD Pharmingen) and APC-labeled anti-IL4 antibody (BD Pharmingen), and flow cytometry analysis was performed.
- FITC-labeled anti-IFN- ⁇ antibody BD Pharmingen
- PE-labeled anti-IL17 antibody BD Pharmingen
- APC-labeled anti-IL4 antibody BD Pharmingen
- flow cytometry analysis was performed.
- the ratio of CD4 + T cells is shown in FIG. 9 (A). Further, the real values of CD4 + T cells are shown in FIG. 9 (B). As is clear from FIG. 9 (A), the proportion of CD4 + T cells in the CD4 + CD45RB high administration group was 47.6%, whereas CD4 + CD45RB high / Gr-1 high CD11b + CD11c + administration The proportion of CD4 + T cells in the group was 6.02%. Moreover, as is clear from FIG. 9 (B), the compared with even CD4 + CD45RB high dose group for real values of CD4 + T cells CD4 + CD45RB high / Gr-1 high CD11b + CD11c + treatment group significantly There were few. These results, the Gr-1 high CD11b + CD11c + cells to suppress the onset CD4 + T cell-dependent colitis by inhibiting the proliferation of CD4 + T cells has been suggested.
- CD4 + CD25 - T cells cultured alone, CD4 + CD25 - co-culture with T cells and Gr-1 low CD11b + CD11c + cells
- CD4 + CD25 ⁇ T cells, Gr-1 low CD11b + CD11c + cells and Gr-1 high CD11b + CD11c + cells were co-cultured.
- staining with Annexin using MEBCYTO-Apoptosis Kit (MBL) staining with Percp-Cy5.5-labeled anti-CD4 antibody (Bio Legend) and subjecting to flow cytometry, Annexin-positive CD4 + T cell The percentage was analyzed.
- the obtained cDNA was hybridized with GeneChip (registered trademark) Mouse Genome 430A 2.0 Array (Affymetrix), and then scanned using GeneArray Scanner (Affymetrix). Genespring software (Agilent Technologies) was used for the analysis.
- FIG. CD antigen gene shown in Figure 11 the 518 gene including the transcription factor genes and cytokine genes, Gr-1 high CD11b + CD11c + the high expression levels should have Gr-1 low CD11b + CD11c + cells than three times more cells Became clear.
- the 518 gene including the transcription factor genes and cytokine genes, Gr-1 high CD11b + CD11c + the high expression levels should have Gr-1 low CD11b + CD11c + cells than three times more cells Became clear.
- about 35% (179/518 genes) of these genes are genes whose expression is induced depending on the anti-inflammatory cytokine IL-10 and the transcription factor Stat3.
- 179 genes 95 genes whose expression level was 4 times or more higher in Gr-1 high CD11b + CD11c + cells than in Gr-1 low CD11b + CD11c + cells are shown in Table 1.
- the transcription factor Stat3 is a transcription factor that is activated by inducing phosphorylation of tyrosine by stimulation with IL-10 or IL-6 family
- Gr-1 high CD11b + CD11c + cells and Gr-1 low CD11b + CD11c + cells are present in the large intestine of IL-10-deficient mice at the same rate as wild-type mice. It has been shown.
- wild-type mouse-derived Gr-1 low CD11b + CD11c + cells only with the co-culture as well as wild-type mouse-derived Gr-1 low CD11b + CD11c + cells and wild-type mouse-derived Gr-1 high CD11b + CD11c + cells was co-cultured.
- a 96-well U-bottom plate was used for the culture, and the culture was performed for 72 hours under conditions of 37 ° C. and 5% CO 2 .
- 56 ⁇ h after the start of the culture 1 ⁇ Ci [ 3 H] thymidine was added to each well, and further cultured for 16 hours. Then, the cells were collected on a filter mat and the radioactivation ability was measured.
- (A) shows the results of Gr-1 high CD11b + CD11c + cells derived from myeloid cell-specific Stat3 deficient mice
- (B) shows the results of Gr-1 high CD11b + CD11c + cells derived from IL-10 deficient mice. .
- FIGS. 16 (A) shows the results of Gr-1 high CD11b + CD11c + cells derived from myeloid cell-specific Stat3 deficient mice
- FIGS. 16 (B) shows the results of Gr-1 high CD11b + CD11c + cells derived from IL-10 deficient mice.
- Gr-1 high CD11b + CD11c + cells derived from wild-type mice suppressed Gr-1 low CD11b + CD11c + cell-dependent T cell proliferation, but myeloid Lineage-specific Stat3-deficient mouse-derived Gr-1 high CD11b + CD11c + cells and IL-10-deficient mouse-derived Gr-1 high CD11b + CD11c + cells are both Gr-1 low CD11b + CD11c + cell-dependent T It had no ability to suppress cell growth.
- Gr-1 high CD11b + CD11c + cells from wild type and IL-10 deficient mice were cultured for 72 hours in the presence or absence of 100 ng / ml IL-10, respectively, and then CD4 + CD25 ⁇ T cells and Gr-1 Low CD11b + CD11c + cells were added and further co-cultured for 72 hours.
- CD4 + CD25 ⁇ T cells and wild type mouse-derived Gr-1 low CD11b + CD11c + cells were co-cultured for 72 hours. After 56 hours from the start of co-culture, 1 ⁇ Ci [ 3 H] thymidine was added, and the cells were further cultured for 16 hours. Then, the cells were collected on a filter mat and the radioactivation ability was measured.
- Example 6 From the above results of Example 6, it is important for suppression of intestinal inflammation that IL-10 activates transcription factor Stat3 in Gr-1 high CD11b + CD11c + cells and induces T cell activation suppression ability. It has been suggested.
- Example 7 Examination of enteritis treatment effect by wild type Gr-1 high CD11b + CD11c + cell administration to myeloid cell specific Stat3 deficient mice.
- tissue destruction due to uncontrollable production of inflammatory cytokines in innate immune cells and an increase in effector T cells (especially Th1 cells) have been reported (Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, et al. (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
- Gr-1 high CD11b + CD11c + cells were recovered from large intestine LPs of wild-type mice backcrossed to C57BL / 6J using FACSAria.
- Myeloid cell-specific Stat3-deficient mice (LysM-Cre; Stat3 F / F ) were treated with 7 ⁇ 10 7 wild-type Gr-1 high CD11b + CD11c + cells twice (4th and 6th week after birth). It was intraperitoneally administered (Gr-1 high CD11b + CD11c + cell administration group).
- myeloid cell-specific Stat3-deficient mice (PBS administration group) administered with PBS instead of wild-type Gr-1 high CD11b + CD11c + cells, and wild-type mice backcrossed to untreated C57BL / 6J Using.
- PBS administration group administered with PBS instead of wild-type Gr-1 high CD11b + CD11c + cells
- wild-type mice backcrossed to untreated C57BL / 6J Using.
- CD4 + T cells were collected from the spleen and cultured in the presence or absence of anti-CD3 antibody (1 ⁇ g / ml soluble) for 24 hours, and then the IFN- ⁇ concentration and IL-17 concentration in the culture supernatant were determined by ELISA. It was measured.
- a tissue specimen was prepared, stained with hematoxylin and eosin, and observed with a microscope.
- FIG. 19 shows the results of measuring the IFN- ⁇ concentration and IL-17 concentration in the culture supernatant by ELISA.
- FIG. 20 shows colon tissue specimen images of the PBS administration group (A) and the Gr-1 high CD11b + CD11c + cell administration group (B).
- the amount of CD4 + T cells was increased by anti-CD3 antibody stimulation regardless of whether or not Gr-1 high CD11b + CD11c + cells were administered.
- IFN- ⁇ and IL-17 have been shown to be produced.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Il a été découvert que les cellules myéloïdes, qui sont présentes dans la lamina propria d'animaux sains et sont hautement positives pour Gr-1, positives pour CD11b et positives pour CD11c, peuvent induire une apoptose des lymphocytes T et, en retour, inhiber l'activation des lymphocytes T. Ces cellules myéloïdes sont grandement utiles comme ingrédients actifs d'un immunomodulateur qui est applicable à la prévention ou au traitement d'une maladie intestinale inflammatoire, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-241034 | 2009-10-20 | ||
JP2009241034 | 2009-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011049053A1 true WO2011049053A1 (fr) | 2011-04-28 |
Family
ID=43900279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/068305 WO2011049053A1 (fr) | 2009-10-20 | 2010-10-19 | Cellules myéloïdes inhérentes à la muqueuse intestinale inhibant l'activation des lymphocytes t et leur utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011049053A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020158914A1 (fr) * | 2019-02-01 | 2020-08-06 | 国立大学法人京都大学 | Procédé de détection de cellules |
-
2010
- 2010-10-19 WO PCT/JP2010/068305 patent/WO2011049053A1/fr active Application Filing
Non-Patent Citations (6)
Title |
---|
GOUNARIS E ET AL.: "Cysteine-cathepsin activity reveals dynamics of polyp growth.", GASTROENTEROLOGY, vol. 134, no. 4, SUP, 2008, pages A578, T1859 * |
HIROI T ET AL.: "Biological function of mucosal dendritic cells.", BIO CLINICA, vol. 20, no. 6, 2005, pages 513 - 519 * |
NAOKO KAYAMA ET AL.: "Chokan Men'eki to Cho Shikkan IV. Chokan Men'eki to Ensho-sei Cho Shikkan", ALLERGOLOGY & IMMUNOLOGY, vol. 17, no. 7, June 2010 (2010-06-01), pages 1182 - 1186 * |
OSTRAND-ROSENBERG S ET AL.: "Myeloid-derived suppressor cells: linking inflammation and cancer.", J IMMUNOL., vol. 182, no. 8, April 2009 (2009-04-01), pages 4499 - 4506, XP002588069, DOI: doi:10.4049/JIMMUNOL.0802740 * |
SONG X ET AL.: "Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity.", CANCER SCIENCE, vol. 100, no. 2, February 2009 (2009-02-01), pages 334 - 340 * |
TAKACHIKA HIROI ET AL.: "Nenmaku-kei Kosankyu-yo Jujo Saibo ni yoru Men'eki Kan'yo Seigyo", ANNUAL REVIEW MEN'EKI, vol. 2007, 2006, pages 221 - 230 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020158914A1 (fr) * | 2019-02-01 | 2020-08-06 | 国立大学法人京都大学 | Procédé de détection de cellules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maroof et al. | Posttranscriptional regulation of Il10 gene expression allows natural killer cells to express immunoregulatory function | |
Fantini et al. | Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression | |
Ostanin et al. | T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade | |
US11471517B2 (en) | Compositions and methods for preventing and treating graft versus host disease | |
JP2021184752A (ja) | 免疫疾患の治療のための高効能幹細胞の選別方法 | |
KR102100307B1 (ko) | 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도 | |
KR102360824B1 (ko) | Th-gm 세포 기능 조절 방법 및 조성물 | |
Brooks et al. | CD14 and ALPK1 affect expression of tight junction components and proinflammatory mediators upon bacterial stimulation in a colonic 3D organoid model | |
WO2011049053A1 (fr) | Cellules myéloïdes inhérentes à la muqueuse intestinale inhibant l'activation des lymphocytes t et leur utilisation | |
Messerschmidt et al. | TSLP/dendritic cell axis promotes CD4+ T cell tolerance to the gut microbiome | |
Xu et al. | IL-17-producing γδT cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1+ CD11b+ myeloid-derived suppressor cells | |
KR101273747B1 (ko) | Sta-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물 | |
CN112805017A (zh) | 使用先天淋巴样细胞抑制小胶质细胞激活 | |
EP3493835A1 (fr) | Méthode d'induction ex vivo de lymphocytes suppresseurs à l'aide de protéines provenant de parasites d'helminthes. | |
Peres et al. | Anti-TNF-induced IL-27 modulates regulatory T cell responses in patients with IBD that respond to therapy | |
Fu | The Transcriptional Regulation and Function of IL-9 in Allergic Lung Inflammation and Tumor Growth | |
Yi | Dusp4 Regulates Intestinal Inflammation and Tumorigenesis | |
Pizzarello | Effects of Dietary and Environmental Exposures on Infant Immune Development | |
De Roo | THE ROLE OF RUNX TRANSCRIPTION FACTORS IN HUMAN NATURAL KILLER AND INNATE LYMPHOID CELL DIFFERENTIATION AND FUNCTION | |
CN117230186A (zh) | 谷氨酰胺转运体ASCT2作为靶点在制备治疗Tfh相关自身免疫性疾病药物中的应用 | |
Flavell et al. | RNA m6A demethylase ALKBH5 regulates the development of γδ T cells | |
Seillet et al. | PD-1 regulates ILC3-driven intestinal immunity and homeostasis | |
Volova et al. | Donor-specific production of cytokines by blood cells under the influence of immunomodulators: New aspects of a personalized approach in medicine | |
Zhang et al. | The dephosphorylation of FADD at S191 induces an excessive expansion of TCRαβ+ IELs in the intestinal mucosa | |
Jones | Investigating innate lymphoid cell function in primary lymphoid tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10824902 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 10824902 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |